Mi­rati's KRAS drug looks like the ear­ly fa­vorite in colon can­cer with new da­ta, putting the pres­sure square on Am­gen

With Am­gen al­ready pro­vid­ing proof-of-con­cept for KRAS in­hibitors with its so­tora­sib, Mi­rati Ther­a­peu­tics is piec­ing to­geth­er a fol­low-up ef­fort in lung can­cer with da­ta it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.